Innate Pharma S.A.

Innate Pharma S.A. is a biotechnology company specializing in the development of innovative immunotherapies for cancer patients. As a clinical-stage firm, it focuses on leveraging innate immunity and advanced antibody engineering to create life-enhancing cancer drugs. The company’s research centers on three major therapeutic modalities: multi-specific natural killer (NK) cell engagers developed through its proprietary ANKET® platform, antibody-drug conjugates (ADCs), and monoclonal antibodies (mAbs). Its pipeline encompasses candidates for treating various cancers, including the differentiated ADC IPH4502 for solid tumors and notable monoclonal antibodies such as lacutamab, targeting T cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer. Innate Pharma maintains strategic collaborations with leading pharmaceutical companies, including Sanofi and AstraZeneca, and partners with academic institutions to further innovation. Operating internationally, the company plays a significant role in advancing therapeutic options for cancers with high unmet medical needs, aiming to transform treatment standards and drive scientific progress in oncology.